Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

Gene-edited crops are no safer than GMOs, and fast-tracking regulatory approval could trigger a costly backlash.

New research breaks down how scientists use CRISPR technology to lower cholesterol. The cholesterol-lowering effects could be permanent.